• Resistance/ Cross-Resistance

Emtricitabine/tenofovir (Truvada) versus Zidovudine/lamivudine (Combivir), Both in Combination with Efavirenz (Sustiva): 3-year Data   - 8/04/07

Significant Sparing of Lipoatrophy Results from Treatment of HIV Patients with Kaletra + Combivir Induction followed by Kaletra Monotherapy Compared with Sustiva + Combivir - 3/02/07

[P392] Safety and antiviral activity of the novel CCR5 antagonist aplaviroc in combination with zidovudine+lamivudine in HIV-infected therapy naive subjects 11/27/06

[P199] Study 934: significantly lower frequency of the M184V mutation on FTC + TDF + EFV compared to combivir + EFV at week 96 11/27/06

[P6] Efficacy and safety of Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz (EFV) compared to fixed dose Zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naive patients 11/27/06

[P53] Impact of switching virologically suppressed, HIV-infected patients from fixed-dose zidovudine/lamivudine (CBV) to fixed-dose tenofovir DF/emtricitabine (TVD) 11/27/06

Data Safety Monitoring Board (DSMB) Recommends Continuation of Maraviroc Phase III Development Program - 1/27/06

GlaxoSmithKline Perspective on Data Involving Combivir Published in the New England Journal of Medicine - 1/20/06

New England Journal of Medicine Publishes Study Results Showing Superiority of Combination of Once Daily Truvada/Sustiva versus Twice Daily Combination of Combivir/Sustiva - 1/20/06

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Treatment-naive HIV Patients - 1/17//06

Patients Taking Fixed-dose Combination Pills Are More Likely to Refill Prescriptions on Time - 12/05/05

Report on the XIV International HIV Drug Resistance Workshop: Parts 1-3 - 7/06/05

Gilead Begins Roll-out of Truvada in European Union at Higher Price than GSK's Combivir - 4/18/05

NIH Panel Defends Nevirapine Perinatal HIV Prevention Study - 4/08/05

A New Triple Nucleoside Analogue Regimen Produces a Rapid, Durable HIV RNA Decrease with a Good Immunologic Response and a Good Safety Profile - 3/04/05

Combivir Plus PI Kaletra HIV Prophylaxis May Increase Tolerability - 2/04/05

Gilead Announces Preliminary 48-week Data Comparing Tenofovir and Emtricitabine to Combivir, Both in Combination with Efavirenz - 2/04/05

Combination of Fixed Dose Tenofovir/Emtricitabine plus Efavirenz Has Significantly Greater Responses vs Fixed Dose Zidovudine/Lamivudine plus Efavirenz in Treatment-naive Patients: An Interim Analysis - 11/01/04

Efficacy of Three NRTIs (Trizivir) or Two NRTIs (Combivir) Plus Nevirapine as Simplified Strategies in HIV Patients with Viral Suppression  - 11/01/04

Comparative Study of Combivir + Efavirenz (2 Class Triple Therapy) versus Trizivir + Tenofovir (Single Class Quadruple Therapy) in Initial Therapy for HIV - 11/01/04

The Ideal Nucleoside/Nucleotide Backbone - 09/01/04

Comparison of Triple Nucleoside Treatment with Abacavir plus the Lamivudine/ Zidovudine Combination Tablet (COM) with Indinavir/ COM - 07/28/04

Trizivir or Combivir Plus Nevirapine as Simplified Strategies Shows Viral and Immunologic Efficacy and Improved Lipid Abnormalities  - 07/23/04

Mitochondrial Damage and DNA Depletion in Cord Blood and Umbilical Cord from Infants Exposed in Utero to Combivir 04/05/04

Comparison of Generic Zidovudine + Lamivudine (Cipla, Duovir) and GlaxoSmithKline Brand (Combivir) Tablets 04/05/04